Detailed Information on Publication Record
2014
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
BUCHLER, Tomáš, Tomáš PAVLÍK, Bohuslav MELICHAR, Zbyněk BORTLÍČEK, Zuzana USIAKOVÁ et. al.Basic information
Original name
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
Authors
BUCHLER, Tomáš (203 Czech Republic), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Zuzana USIAKOVÁ (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, guarantor, belonging to the institution), Igor KISS (203 Czech Republic), Milan KOHOUTEK (203 Czech Republic), Vera BENESOVA (203 Czech Republic), Rostislav VYZULA (203 Czech Republic), Jitka ABRAHAMOVA (203 Czech Republic) and Radka OBERMANNOVA (203 Czech Republic)
Edition
BMC CANCER, London, BIOMED CENTRAL LTD, 2014, 1471-2407
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.362
RIV identification code
RIV/00216224:14110/14:00075704
Organization unit
Faculty of Medicine
UT WoS
000336688900002
Keywords in English
Colorectal cancer; Bevacizumab; Capecitabine; 5-fluorouracil; Oxaliplatin
Tags
Tags
International impact, Reviewed
Změněno: 24/4/2015 13:07, Soňa Böhmová
Abstract
V originále
Background: Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC). Methods: A national registry containing anonymised individual data on patients treated with targeted therapies was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab combined with either FOLFOX regimen (n = 1,218, 55.6%) or XELOX regimen (n = 973, 44.4%) were included in the present analysis. Results: No statistically significant difference in survival was observed between the two groups, with median overall survival (OS) of 27.0 months (95% confidence interval [CI] 24.6-29.5 months) and 30.6 months (95% CI 27.8-33.4 months) for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p = 0.281). Median progression-free survival (PFS) was 11.4 months (95% CI 10.7-12.1 months) for FOLFOX/bevacizumab and 11.5 months (95% CI 10.8-12.3 months) for XELOX/bevacizumab (p = 0.337). The number of metastatic sites was identified as the most significant predictor of PFS and, together with the presence/absence of metastatic disease at diagnosis, also for OS. Conclusions: According to this large registry-based analysis, XELOX and FOLFOX regimens have similar effectiveness for use in combination with bevacizumab in the first-line treatment of mCRC. Multiple metastatic sites and the presence of metastatic disease at diagnosis were the strongest negative predictors of OS regardless of backbone chemotherapy regimen.